News – Seaport Therapeutics

Press Release - 2025-02-21

Seaport

Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies

Press Release - 2025-02-12

Seaport

Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Press Release - 2025-01-06

Seaport Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Press Release - 2024-12-11

Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Press Release - 2024-11-20

Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

Press Release - 2024-11-05

Seaport Therapeutics Names Lauren White as Chief Financial Officer

Press Release - 2024-10-21

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Press Release - 2024-08-13

Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors

Press Release - 2024-06-18

Seaport Therapeutics Appoints Seasoned Executives to Management Team

Press Release - 2024-05-09

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting